Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Plasmapheresis to eliminate immunosuppressive alemtuzumab levels in a child with disseminated adenovirus infection after allogeneic stem cell transplantation

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Serum alemtuzumab concentrations, load of adenovirus (AdV) and lymphoid recovery in relation to HSCT timeline.

References

  1. Zandvliet ML, Falkenburg JH, van Liempt E, Veltrop-Duits LA, Lankester AC, Kalpoe JS, et al. Combined CD8+ and CD4+ adenovirus hexon-specific T-cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection. Haematologica. 2010;95:1943–51.

    Article  CAS  Google Scholar 

  2. Feuchtinger T, Lücke J, Hamprecht K, Richard C, Handgretinger R, Schumm M, et al. Detection of adenovirus-specific T-cells in children with adenovirus infection after allogeneic stem cell transplantation. Br J Haematol. 2005;128:503–9.

    Article  Google Scholar 

  3. Ibrahim RB, Liu C, Cronin SM, Murphy BC, Cha R, Swerdlow P, et al. Drug removal by plasmapheresis: an evidence-based review. Pharmacotherapy. 2007;27:1529–49.

    Article  CAS  Google Scholar 

  4. Zhang P, Curley CI, Mudie K, Nakagaki M, Hill GR, Roberts JA, et al. Effect of plasmapheresis on ATG (Thymoglobulin) clearance prior to adoptive T cell transfer. Bone Marrow Transplant 2019;54:2110–6.

    Article  CAS  Google Scholar 

  5. Admiraal R, Jol-van der Zijde CM, Furtado Silva JM, Knibbe CAJ, Lankester AC, Boelens JJ, et al. Population pharmacokinetics of alemtuzumab (Campath) in pediatric hematopoietic cell transplantation: towards individualized dosing to improve outcome. Clin Pharmacokinet. 2019;58:1609–20.

    Article  CAS  Google Scholar 

  6. Admiraal R, Nierkens S, de Witte MA, Petersen EJ, Fleurke GJ, Verrest L, et al. Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis. Lancet Haematol. 2017;4:e183–91.

    Article  Google Scholar 

  7. Marsh RA, Lane A, Mehta PA, Neumeier L, Jodele S, Davies SM, et al. Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT. Blood. 2016;127:503–12.

    Article  CAS  Google Scholar 

  8. Lugthart G, Oomen MA, Jol-van der Zijde CM, Ball LM, Bresters D, Kollen WJ, et al. The effect of cidofovir on adenovirus plasma DNA levels in stem cell transplantation recipients without T cell reconstitution. Biol Blood Marrow Transplant. 2015;21:293–9.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank all providers at Department of Pediatric Stem Cell Transplantation, Willem Alexander Children’s Hospital, Leiden University Medical Center, for their excellent patient care and A. Jansen-Hoogendijk for technical assistance.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Robbert G. M. Bredius.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Achini, F.R., Smiers, F., Jan Zwaginga, J. et al. Plasmapheresis to eliminate immunosuppressive alemtuzumab levels in a child with disseminated adenovirus infection after allogeneic stem cell transplantation. Bone Marrow Transplant 55, 1671–1673 (2020). https://doi.org/10.1038/s41409-020-0837-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-020-0837-1

This article is cited by

Search

Quick links